Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 1998 March;40(1) > Panminerva Medica 1998 March;40(1):75-81





Rivista di Medicina Interna

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6




Panminerva Medica 1998 March;40(1):75-81

lingua: Inglese

Treatment with col­chi­cine and sur­vi­val of ­patients with ascit­ic cir­rho­sis: a dou­ble-blind ran­dom­ized trial

Adhami J. E., Basho J.

From the University Medical Center of Tirana, Albania


Background. In order to ­assess the role of col­chi­cine in the sur­vi­val of cir­rhot­ic ­patients, 52 ­patients were stud­ied.
Methods. The ­patients were divid­ed into two ­groups, ran­dom­ized accord­ing to age. There were no sig­nif­i­cant dif­fer­enc­es in age, sex, etio­log­ic fac­tors, or bio­log­i­cal data. In addi­tion to con­ven­tion­al ther­a­py with diu­ret­ics, the first group was treat­ed with col­chi­cine of 1 mil­li­gram daily for 5 days a week, and the sec­ond group with a pla­ce­bo.
Results. Under the ­action of col­chi­cine, the diu­ret­ics were dis­con­tin­ued ­because the ­ascites dis­ap­peared in 37.93% of the col­chi­cine group, vs 4.35% of the pla­ce­bo group (p<0.01). At time of dis­charge from the clin­ic, ascit­ic fluid dis­ap­peared respec­tive­ly in 72.41% and 26.09% of cases (p<0.001), where­as the recur­rence in the fol­low-up peri­od was 47.62% vs 83.33% (p< 0.1).
Conclusions. Using Kaplan Meier sur­vi­val ­curves, and com­par­ing both ­groups with the Logrank test dur­ing a peri­od of 11 years, it was found that sur­vi­val of the col­chi­cine group was 3 times great­er than that of the pla­ce­bo group (p<0.001).

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail